Zacks Investment Research cut shares of DENTSPLY SIRONA (NASDAQ:XRAY) from a hold rating to a sell rating in a research note issued to investors on Monday, January 8th.
According to Zacks, “Over the last year, DENTSPLY SIRONA traded below the broader industry in terms of prices. The company's higher capital expenditure on product development and tough competition are expected to put margins under pressure. Unfavorable foreign exchange rate and integration risks are the major headwinds in the near term. However robust performance by the company’s flagship dental implants, CAD/CAM systems, imaging systems, treatment centers and orthodontic product platforms hold considerable promise over the long haul. Emerging markets like Asia-Pacific & the Middle East offer healthy growth opportunities on a long-term basis, as they remain vastly untapped with low dental products penetration. The company’s agreements with MedTech bigwigs Patterson Companies in Canada are likely to drive sales. DENTSPLY SIRONA has recently witnessed a rebound in sales in Asia, particularly Japan, and strong growth in Russia. Over the last year, DENTSPLY”
Several other analysts have also recently commented on XRAY. Credit Suisse Group cut DENTSPLY SIRONA to a hold rating and set a $73.00 target price on the stock. in a research report on Friday, January 5th. JPMorgan Chase & Co. upgraded DENTSPLY SIRONA from a neutral rating to an overweight rating and set a $75.00 target price on the stock in a research report on Wednesday, December 13th. Deutsche Bank initiated coverage on DENTSPLY SIRONA in a research report on Friday, December 8th. They issued a buy rating and a $81.00 target price on the stock. HC Wainwright reiterated a hold rating and set a $68.00 price target on shares of DENTSPLY SIRONA in a research report on Thursday, December 7th. Finally, BidaskClub cut DENTSPLY SIRONA from a strong-buy rating to a buy rating in a research report on Saturday, December 2nd. Two analysts have rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of Hold and an average target price of $69.15.
DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $978.99 million. DENTSPLY SIRONA had a positive return on equity of 7.56% and a negative net margin of 20.33%. The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business posted $0.66 EPS. equities research analysts forecast that DENTSPLY SIRONA will post 2.65 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, January 12th. Investors of record on Friday, December 29th were issued a $0.0875 dividend. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.53%. The ex-dividend date of this dividend was Thursday, December 28th. DENTSPLY SIRONA’s payout ratio is -10.06%.
In other DENTSPLY SIRONA news, CFO Nicholas W. Alexos bought 50,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average price of $65.85 per share, with a total value of $3,292,500.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark Thierer bought 77,000 shares of the firm’s stock in a transaction dated Monday, November 13th. The stock was acquired at an average cost of $66.04 per share, with a total value of $5,085,080.00. The disclosure for this purchase can be found here. Insiders own 1.99% of the company’s stock.
Several institutional investors have recently modified their holdings of XRAY. Beach Investment Management LLC. acquired a new stake in shares of DENTSPLY SIRONA in the second quarter worth $3,057,000. Federated Investors Inc. PA boosted its position in DENTSPLY SIRONA by 258.6% during the second quarter. Federated Investors Inc. PA now owns 5,486 shares of the medical instruments supplier’s stock valued at $356,000 after purchasing an additional 3,956 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in DENTSPLY SIRONA during the second quarter valued at $764,000. Commonwealth Bank of Australia boosted its position in DENTSPLY SIRONA by 19.0% during the second quarter. Commonwealth Bank of Australia now owns 1,626 shares of the medical instruments supplier’s stock valued at $104,000 after purchasing an additional 260 shares during the last quarter. Finally, Wells Fargo & Company MN boosted its position in DENTSPLY SIRONA by 24.8% during the second quarter. Wells Fargo & Company MN now owns 855,877 shares of the medical instruments supplier’s stock valued at $55,496,000 after purchasing an additional 169,844 shares during the last quarter. 96.13% of the stock is owned by institutional investors and hedge funds.
DENTSPLY SIRONA Company Profile
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.